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OBJECTIVES We investigated whether the effect of bezafibrate on progression of coronary atherosclerosis
in the BEzafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) was related to
insulin-like growth factor (IGF)-I and glucose-insulin homeostasis.
BACKGROUND BECAIT, the first double-blind, placebo-controlled, randomized, serial angiographic trial of
a fibrate compound, demonstrated that progression of focal coronary atherosclerosis in young
patients after infarction could be retarded by bezafibrate treatment.
METHODS The treatment effects on serum concentrations of IGF-I and insulin-like growth factor
binding protein (IGFBP)-1, as well as on basal and postload glucose and insulin levels, were
examined, and on-trial determinations were related to the angiographic outcome measure-
ments.
RESULTS Bezafibrate treatment resulted in a significant reduction of serum IGF-I levels, both at two
and five years, and on-trial serum IGF-I levels were directly related to changes in both
minimal lumen diameter (r 5 0.25, p , 0.05) and mean segment diameter (r 5 0.29, p ,
0.05). In contrast, none of the available indexes of insulin resistance (homeostasis model
assessment estimate, basal and postload plasma insulin concentrations and serum IGFBP-1
levels) were related to the angiographic changes, nor were they significantly affected by
bezafibrate treatment. Multiple stepwise regression analysis showed that the relation between
on-trial serum IGF-I level and coronary artery disease (CAD) progression was independent
of baseline angiographic score, age, body mass index, serum lipoprotein and plasma fibrinogen
concentrations and measures of glucose–insulin homeostasis.
CONCLUSIONS IGF-I could be implicated in the progression of premature CAD, and a reduction of serum
IGF-I concentration could account partly for the effect of bezafibrate on progression of focal
coronary atherosclerosis. (J Am Coll Cardiol 2000;35:647–54) © 2000 by the American
College of Cardiology
Most of the features of insulin resistance syndrome can be
found in patients who have survived a myocardial infarction
(1) and have been related to the progression of coronary
artery disease (CAD) (2). Insulin resistance syndrome is
characterized by clustering of hyperinsulinemia, hypertri-
glyceridemia, hypertension, obesity and a low high density
lipoprotein (HDL) cholesterol level (3), but other factors
have been suggested as components of insulin resistance
syndrome as well. Insulin-like growth factor binding protein
(IGFBP)-1, which is the best characterized of the binding
proteins for insulin-like growth factor (IGF)-I, has recently
been included among the components of insulin resistance
syndrome (4). Its hepatic synthesis is mainly under insulin
control, and a decreased concentration of IGFBP-1 is
considered a very good marker of insulin sensitivity. How-
ever, six different proteins (IGFBP-1 through IGFBP-6)
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have been shown to bind exclusively to IGF-I and IGF-II,
with no cross-linking to insulin. IGFBP-3 binds 70% to
80% and IGFBP-1 20% to 30% of both IGFs, whereas only
;10% of IGF-I is free. The main function of IGFBPs
seems to be the regulation of IGF-I availability (5).
IGF-I has insulin-like metabolic effects and, predomi-
nantly, growth-promoting actions. Because it is important
for tissue repair and cell proliferation, it has been implicated
in the pathogenesis of atherosclerosis (6). However, clinical
studies have produced conflicting results regarding the
relation between circulating IGF-I and CAD (7–9), and
longitudinal data linking circulating IGF-I to progression of
CAD are still lacking.
The BEzafibrate Coronary Atherosclerosis Intervention
Trial (BECAIT), the first double-blind, placebo-controlled,
randomized, serial angiographic trial of a fibrate compound,
demonstrated that progression of focal coronary atheroscle-
rosis in young survivors of myocardial infarction could be
retarded by bezafibrate treatment (10). The angiographic
effects observed in the bezafibrate-treated patients were
accompanied by significant reductions in very low density
lipoprotein (VLDL) cholesterol, triglycerides and plasma
fibrinogen, as well as an increase in HDL cholesterol (10).
In the present report from BECAIT, the treatment effects
on IGF-I and IGFBP-1 levels, as well as on glucose–insulin
homeostasis, are examined, and on-trial serum levels are
related to the angiographic outcome measurements. Our
results demonstrate that serum IGF-I levels are reduced by
bezafibrate treatment, and that on-trial IGF-I levels are
independently associated with CAD progression in young
survivors of myocardial infarction.
METHODS
Trial design. The rationale, design features and recruit-
ment procedures of the study have been reported (10,11). In
brief, 92 men (,45 years old) who survived a first myocar-
dial infarction were included, all of whom had a serum
cholesterol level of at least 5.2 mmol/liter and a mean serum
triglyceride level of at least 1.6 mmol/liter, or both, as
measured on two occasions after a three-month period of
dietary and life-style intervention. The presence of visually
detectable lesions in at least one coronary segment consti-
tuted a further inclusion criterion. Eligible patients were
randomly assigned to double-blind treatment with bezafi-
brate (200 mg three times daily, n 5 47) or placebo (n 5
45), after having given written, informed consent to partic-
ipate. All participants also continued the pretreatment diet
throughout the study. Selective coronary angiography was
repeated after two and five years. Patients with manifest
diabetes mellitus were not included in the study.
Blood sampling was performed at baseline and then
yearly during the entire treatment period for fasting serum
lipoprotein determinations. IGF-I and IGFBP-1 were mea-
sured on serum samples drawn at baseline and two and five
years after randomization, at which points oral glucose
tolerance tests were also done.
The study protocol was approved by the Ethics Commit-
tee of the Karolinska Institute.
Oral glucose tolerance test. Glucose was ingested in a
dose of 1.75 g/kg body weight in 150 to 200 ml of water
flavored with lemon extract. Venous blood samples were
collected through an indwelling catheter before and 15, 30,
45, 60, 90 and 120 min after glucose intake. Oral glucose
tolerance was assessed according to criteria adopted from
Reaven et al. (12). The plasma insulin response to glucose
ingestion was evaluated by calculation of the insulin area
above the fasting level throughout the 120 min of the test.
The glucose area under the curve indicated the total glucose
area during the oral glucose tolerance test. A relative insulin
resistance index was calculated from the fasting blood
glucose and plasma insulin concentrations using the
computer-solved homeostasis model assessment (HOMA)
(13).
Lipoprotein separation. The major serum lipoproteins
(VLDL, low density lipoprotein [LDL] and HDL) were
determined by a combination of preparative ultracentrifu-
gation and precipitation of apolipoprotein B–containing
lipoproteins, followed by lipid analyses (14). The HDL3
fraction was obtained as a bottom fraction in which choles-
terol was determined after one preparative ultracentrifuge
spin at a density of 1.125 kg/liter (15). For determination of
the LDL particle size distribution, serum samples contain-
ing 1 mg of LDL cholesterol were subjected to 3% to 7.5%
polyacrylamide gradient gel electrophoresis. All three sam-
ples from an individual patient (taken at baseline and two
and five years after randomization) were applied to the same
gel, along with three standard reference proteins (16). The
intra-assay and interassay coefficients of variation for LDL
peak particle size determinations were 1.3% and 2.3%,
respectively.
Assays. Serum apolipoprotein B was determined by radio-
immunoassay. Serum lipoprotein (Lp)(a) was measured
using an enzyme immunoassay (TintElize Lp[a], Biopool,
Umeå, Sweden). Glucose was measured in whole blood by
the glucose oxidase method (17). Plasma insulin was mea-
Abbreviations and Acronyms
BECAIT 5 BEzafibrate Coronary Atherosclerosis
Intervention Trial
HDL 5 high density lipoprotein
HOMA 5 homeostasis model assessment
IGF 5 insulin-like growth factor
IGFBP 5 insulin-like growth factor binding protein
LDL 5 low density lipoprotein
Lp(a) 5 lipoprotein (a)
MLD 5 minimal lumen diameter
MSD 5 mean segment diameter
VLDL 5 very low density lipoprotein
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sured using a double-antibody radioimmunoassay (18).
Serum samples were acid-ethanol extracted to partially
separate IGFBPs from IGF-I. Iodine-125–labeled des(1-
3)IGF-I radioligand was used in the IGF-I radioimmuno-
assay to avoid interference by IGFBP-1 not removed during
the extraction procedure (19). Serum concentrations of
IGFBP-1 in fasting samples were determined by radioim-
munoassay (20). The plasma fibrinogen concentration was
measured by a polymerization test (21).
Coronary angiography. Coronary angiography was per-
formed using the percutaneous transfemoral technique at
baseline and then repeated two and five years later. Quan-
titative computer-assisted evaluation was undertaken with
the Cardiovascular Measurement System (Medis, Nuenen,
The Netherlands) (22) by individuals who had no knowl-
edge of the treatment assignment and the on-trial biochem-
ical determinations, as described (10). Angiograms were
routinely obtained before and within 10 min after intracoro-
nary or sublingual nitroglycerin administration to eliminate
differences in vascular constriction. The minimal lumen
diameter (MLD), which reflects focal atherosclerosis, was
measured at the site of the most severe atherosclerotic lesion
in each segment that reduced the lumen diameter by at least
20%. The mean segment diameter (MSD) was calculated in
all coronary segments, irrespective of the presence of visually
detectable atherosclerosis, as an indicator of diffuse as well
as focal atherosclerosis. Percent diameter stenosis was cal-
culated from the most narrow lesion in each segment with a
diameter reduction of at least 20%. Measurements of MSD
were only undertaken in unoccluded segments and in
segments proximal to an occlusion, whereas MLD and
percent diameter stenosis were set to 0 mm and 100%,
respectively, in occluded segments and distal segments not
recorded. Patients who had coronary angioplasty for clinical
reasons during the study were included in the analyses, but
the segments involved in the procedure and all distal
segments were excluded from subsequent analyses.
Statistical analysis. Continuous variables are presented as
the least squares mean value 6 SEM or median value
(interquartile range); categoric variables are presented as
numbers (percentages). The individual values of skewed
variables were transformed to their natural logarithms be-
fore statistical tests. Per-patient means of MLD, MSD and
percent diameter stenosis were calculated for baseline and
repeat angiograms. The angiographic outcome variables
were median change (D) between the baseline and last
follow-up angiogram for MLD and MSD, and between the
last follow-up and baseline angiogram for percent diameter
stenosis. Only corresponding segments from the baseline
and follow-up angiograms were used in the assessment of
angiographic change. The chi-square test was used for
comparing the distribution of patients according to glucose
tolerance category during the five-year follow-up. The
responses of IGF-I, IGFBP-1 and glucose–insulin variables
to the study drug over time in the bezafibrate and placebo
groups were compared by two-way repeated measures anal-
ysis of variance (ANOVA). The disease progression data
(DMLD, DMSD and D% diameter stenosis) were either
used as continuous variables or divided according to tertiles.
The association between baseline clinical characteristics and
tertiles of angiographic outcome measurements was evalu-
ated by ANOVA. The Tukey-Kramer test was used for
post-hoc analysis when differences between the groups were
significant according to simple or repeated measures
ANOVA. The association between IGF-I, IGFBP-1 and
glucose–insulin variables and disease progression was first
assessed by calculation of univariate Pearson and partial
correlation coefficients. Baseline angiographic measure-
ment, age, on-trial body mass index, serum Lp(a) level and
LDL peak particle size were controlled for when calculating
partial correlation coefficients. A multivariate model was
then generated by multiple stepwise linear regression anal-
ysis using a forward approach to identify variables indepen-
dently correlating with the angiographic outcome variables.
Baseline angiographic measurement, age and on-trial body
mass index were first entered as forced variables. All other
variables were included in the model as independent vari-
ables. Linear regression analysis was also used to assess
interrelations between variables. All statistical tests were
two-sided and p values ,0.05 were considered significant.
RESULTS
Basic characteristics of the patients. The baseline char-
acteristics of the 92 randomized patients have been de-
scribed in detail (10). The present report is based on the 81
patients (42 treated with bezafibrate and 39 with placebo)
who had a baseline angiogram and at least one post-
Table 1. General Characteristics of Patients at Baseline
(n 5 81)
Age (yrs) 42 (39–44)
Body mass index (kg/m2) 26.5 (24.7–29.6)
Hypertension 15 (19%)
Smoking habits
Never smoked 12 (15%)
Previous smokers 51 (63%)
Current smokers 18 (22%)
Tobacco consumption (g/day) 20 (0–30)
Cholesterol (mmol/liter)
Serum 6.82 (5.98–7.83)
VLDL 0.98 (0.72–1.45)
LDL 4.63 (3.87–5.36)
HDL 1.02 (0.93–1.27)
Triglycerides (mmol/liter)
Serum 2.18 (1.62–3.16)
VLDL 1.65 (1.10–2.23)
LDL 0.41 (0.35–0.51)
HDL 0.16 (0.14–0.18)
Data are presented as median value and interquartile range or number (%) of subjects
(%).
HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; VLDL 5 very
low density lipoprotein.
649JACC Vol. 35, No. 3, 2000 Ruotolo et al.
March 1, 2000:647–54 IGF-I and CAD Progression
treatment angiogram. The two study groups were compa-
rable in terms of baseline clinical and angiographic data, as
well as the use of concomitant medications. The partici-
pants had a mean age of 42 years and were moderately
overweight and dyslipidemic (Table 1). Hypertension and
cigarette smoking were relatively frequent in this group.
Patients with diabetes mellitus were not recruited accord-
ing to the inclusion criteria. However, 67% of participants
had borderline or decreased oral glucose tolerance (Table 2).
The percentage of patients with decreased glucose tolerance
increased significantly during the study, and 10% of the
participants developed manifest diabetes mellitus.
Treatment effects on glucose–insulin homeostasis,
IGF-I and IGFBP-1. Baseline and on-trial glucose and
insulin responses to the oral glucose tolerance test in the two
study groups are shown in Table 3. No significant differ-
ences were observed between the study groups in either
baseline or on-trial responses. However, the glucose and
incremental insulin areas increased significantly over time in
both groups. The relative insulin resistance assessed by
HOMA was also similar between the study groups over
time, even though a slight improvement was observed in the
bezafibrate as compared with the placebo group at five years
(p 5 0.06).
At baseline, serum IGF-I and IGFBP-1 levels did not
differ significantly between the study groups (Fig. 1). Beza-
fibrate treatment resulted in a significant reduction of serum
IGF-I levels, both at two years (173 6 8 vs. 198 6 8
mg/liter, p , 0.05) and five years (165 6 8 vs. 196 6 8
mg/liter, p , 0.01) (two-way repeated measures ANOVA:
group p 5 0.03, time p 5 0.01, interaction p 5 0.18),
although serum IGFBP-1 levels did not change (two-way
repeated measures ANOVA: group p 5 0.0005, time p 5
0.91, interaction p 5 0.90) (Fig. 1).
Relations of IGF-I and IGFBP-1 to glucose–insulin and
lipoprotein variables. On-trial serum IGF-I levels did not
correlate with any lipoprotein variable, except for a signifi-
cant positive correlation with the on-trial serum Lp(a) level
(r 5 0.25, p , 0.05). Significant correlations were also
observed between changes (between on-trial and baseline)
in IGF-I levels and LDL peak particle size (r 5 20.28, p ,
0.05).
Serum IGFBP-1 levels were significantly correlated with
body mass index (basal: r 5 20.36, p , 0.01; on-trial: r 5
20.48, p , 0.001), serum triglycerides (or VLDL choles-
terol and triglycerides) (basal: r 5 20.29, p , 0.01; on-trial:
r 5 20.32, p , 0.01) and HOMA (or plasma insulin and
glucose and insulin areas under the curve) (basal: r 5 20.49,
p , 0.001; on-trial: r 5 20.55, p , 0.001) at baseline and
during the trial.
Relations to angiographic outcome measurements. Ta-
ble 4 shows univariate Pearson and partial correlation
coefficients between on-trial serum concentrations of
IGF-I, IGFBP-1 and glucose–insulin responses to the oral
glucose tolerance test and angiographic outcome variables,
the last with control for baseline angiographic score, age and
on-trial body mass index, Lp(a) levels and LDL size.
On-trial serum IGF-I levels were directly related to both
DMLD (r 5 0.25, p , 0.05) and DMSD (r 5 0.29, p ,
0.05) after controlling for confounders. In contrast, serum
IGFBP-1 levels and the ratio of IGF-I to IGFBP-1 did not
Table 2. Distribution of Patients According to Oral Glucose
Tolerance or Presence of Manifest Diabetes Mellitus Over the
Five-Year Study Period
Glucose Tolerance
Category Baseline 2 Years 5 Years
Normal 27 (33%) 24 (30%) 12 (15%)
Borderline 25 (31%) 16 (20%) 17 (21%)
Decreased 29 (36%) 41 (51%) 44 (54%)
Manifest diabetes mellitus 0 (0%) 0 (0%) 8 (10%)
Data are presented as number (%) of subjects. Oral glucose tolerance was defined
according to Reaven et al. (12). The distribution of patients according to glucose
tolerance category is significantly different over time (p 5 0.02, chi-square test). No
differences in glucose tolerance were observed between patients receiving placebo or
bezafibrate throughout the study.
Table 3. Baseline and On-Trial Body Mass Index, Glucose and Insulin Responses to the Oral Glucose Tolerance Test and
Homeostasis Model Assessment
Variable Study Group Baseline 2 Years 5 Years
p Value*
Group Time Interaction
BMI (kg/m2) Bezafibrate 27.6 6 0.6 28.7 6 0.6 29.0 6 0.6 0.55 0.15 0.94
Placebo 26.5 6 0.6 27.2 6 0.6 27.5 6 0.6
GlucoseAUC
(mmol/liter 3 min)
Bezafibrate 9,279 6 403 10,162 6 398 10,263 6 450 0.91 0.02 0.67
Placebo 9,109 6 413 9,736 6 413 10,583 6 445
InsulinAUC
(mg/ml 3 min)
Bezafibrate 9,878 6 1,175 12,496 6 1,191 15,325 6 1,329 0.23 ,0.0001 0.54
Placebo 9,746 6 1,220 11,039 6 1,220 15,448 6 1,313
HOMA index Bezafibrate 3.9 6 0.4 4.6 6 0.4 4.3 6 0.5 0.06 0.30 0.85
Placebo 3.8 6 0.4 4.5 6 0.4 4.5 6 0.5
*Two-way repeated measures analysis of variance. Data are presented as the least squares mean value 6 SEM.
BMI indicates body mass index; glucoseAUC, total glucose area under curve throughout the oral glucose tolerance test (OGTT); HOMA 5 relative insulin resistance by
homeostasis model assessment; insulinAUC, insulin area under curve above fasting level throughout the OGTT.
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show any significant relations to the angiographic outcome
measurements. Significant relations of serum IGF-I levels
to the progression of coronary lesions during the trial were
also observed when patients were grouped according to
tertiles of the angiographic outcome measurements (Fig. 2).
The low tertile group comprises patients who progressed the
least; the high tertile group those who progressed the most.
Serum IGF-I levels were significantly related to changes in
both MLD and MSD (i.e., patients who progressed less had
lower, whereas those who progressed more had higher
serum IGF-I levels) (ANOVA: p 5 0.05 for DMLD, p 5
0.02 for DMSD; p , 0.05 high vs. both low and medium
tertiles).
Multiple stepwise regression analysis was also applied to
study the independent relations of on-trial IGF-I,
IGFBP-1 and glucose–insulin responses to the oral glucose
tolerance test to the angiographic outcome measurements
(Table 4). Baseline angiographic score, age and on-trial
body mass index were entered as forced variables in the
model. On-trial serum IGF-I levels were found to be
independently and directly related to both DMLD and
DMSD in this model, accounting for 5% and 7% of the
multiple R2, respectively. The relations of on-trial serum
IGF-I levels to CAD progression were independent of
on-trial serum lipoprotein (HDL3 cholesterol, apolipopro-
tein B, Lp[a] and LDL size) and plasma fibrinogen levels, as
well as glucose–insulin responses (glucose and insulin areas
under the curve).
DISCUSSION
The present study shows an independent association be-
tween on-trial serum total IGF-I levels and CAD progres-
sion in young male survivors of myocardial infarction and
suggests that the reduced progression of focal coronary
atherosclerosis seen in bezafibrate-treated patients could be
at least partly due to the significant reduction of serum
IGF-I levels obtained with bezafibrate treatment. In con-
trast, none of the available indexes of insulin resistance
(HOMA or plasma insulin and serum IGFBP-1 levels)
showed any significant relation to the angiographic outcome
measurements.
IGF-I and CAD. It has recently been suggested by many
studies that circulating IGF-I might be implicated in the
pathogenesis of CAD. IGF-I is the mediator of most of the
mitogenic effects of growth hormone. It is known to be a
potent regulator of vascular smooth muscle cell proliferation
in vitro (23,24), and its expression is significantly increased
in smooth muscle cells contained in atherectomy specimens
from human plaques causing restenosis after percutaneous
transluminal coronary angioplasty (25). Frystyk et al. (26)
have suggested that the decrease of circulating total IGF-I
after administration of the somatostatin analogue lanreotide
could be responsible for the improvement in the long-term
outcome after percutaneous transluminal coronary angio-
plasty. In addition, exposure of vascular allografts to IGF-I
increases the vascular expression of IGF-I ligand and
receptor proteins and accelerates atherosclerosis in rats by
inducing myointimal proliferation and intimal thickening
(27). Therefore, IGF-I’s effects on the proliferation and
migration of vascular smooth muscle cells into the intima
could potentially be involved in the progression of coronary
atherosclerosis in BECAIT.
However, previous clinical studies did not support the
hypothesis of a positive relation between circulating IGF-I
and the presence of CAD (7–9). Spallarossa et al. (7) have
recently reported that serum concentrations of IGF-I are
Figure 1. Serum IGF-I (upper panel) and IGFBP-1 (lower
panel) levels at baseline and at two and five years after random-
ization in the two study groups (circles 5 placebo group;
squares 5 bezafibrate group). Data are presented as the least
squares mean value 6 SEM. Data were analyzed by two-way
repeated measures analysis of variance (IGF-I: group p 5 0.03,
time p 5 0.01, interaction p 5 0.18; IGFBP-1: group p 5 0.0005,
time p 5 0.91, interaction p 5 0.90). *p , 0.05, **p , 0.01
between the two study groups (post-hoc Tukey-Kramer test).
651JACC Vol. 35, No. 3, 2000 Ruotolo et al.
March 1, 2000:647–54 IGF-I and CAD Progression
reduced in patients with significant coronary stenosis,
whereas Botker et al. (9) were unable to show any associa-
tion between serum total or free IGF-I levels and the
presence of CAD in a smaller number of patients. More-
over, Janssen et al. (8) have shown that high fasting serum
free IGF-I levels are associated with less atherosclerotic
plaques and a lower prevalence of CAD in an elderly group
of patients. It is noteworthy that all of these reports (7–9)
are based on cross-sectional studies and include mostly
patients .45 years old. Some of these studies include both
men and women, or only patients with normal glucose
tolerance or moderately obese individuals. In contrast,
BECAIT is a longitudinal, serial angiographic study of male
patients ,45 years old who have survived a myocardial
infarction, with a mean body mass index of 27 kg/m2 (range
20 to 36). BECAIT includes a substantial proportion of
patients with abnormal glucose tolerance, many of whom
developed manifest diabetes during the five-year follow-up
period. Our data are in agreement with the hypothesis
suggesting that increased IGF-I activity associated with
insulin resistance and decreased IGFBP-1 levels may pro-
mote benign hyperplasia, such as atherosclerosis, and with
the notion that hyperinsulinemia could stimulate intimal
hyperplasia indirectly through IGF-I (28). However, stim-
ulation of smooth muscle cell proliferation may not be the
only mechanism by which IGF-I could promote progression
of CAD in BECAIT, because the on-trial serum IGF-I
level, although independently related to CAD progression,
was directly associated with the serum Lp(a) concentration
and indirectly related to the LDL peak particle size.
Determinants of IGF-I. Serum levels of IGF-I and
IGFBP-1 are dependent on age, diet, physical activity,
growth hormone levels (29–31) and genetic factors (32,33).
The heritability of serum IGF-I levels has been reported to
be higher than that of IGFBP-1 and insulin levels, as well
as independent of the genetic influences on these two
variables (33). The young survivors of myocardial infarction
participating in BECAIT had normal serum total IGF-I
concentrations, whereas their IGFBP-1 levels were mark-
edly decreased (31), the latter secondary to insulin resistance
with ensuing hyperinsulinemia (5,34). This means that the
proportion of IGF-I not bound to IGFBP-1 was increased
due to a rise in either the free, biologically active fraction or
the fraction bound to IGFBP-3, or both. However, it
should be taken into account that the in vivo production of
IGFBP-3 is regulated primarily by IGF-I, whereas in vitro
IGFBP-3 appears to be stimulated by various growth
factors.
Effects of bezafibrate. The present study demonstrates a
significant reduction of serum IGF-I levels by long-term
bezafibrate treatment. The mechanisms by which fibrates
lower serum IGF-I levels are unclear. Fibrates are known to
Figure 2. Serum IGF-I levels according to tertiles of angiographic
outcome measurements in all participants. Data are presented as
the least squares mean value 6 SEM. Data were analyzed by
analysis of variance (DMLD p 5 0.05; DMSD p 5 0.02; D%
diameter stenosis p 5 0.38). *p , 0.05 vs. either low or medium
tertile groups (post-hoc Tukey-Kramer test).
Table 4. Univariate and Multivariate Stepwise Regression Analyses of the Relations of On-Trial Body Mass Index, Glucose and
Insulin Responses to the Oral Glucose Tolerance Test, Homeostasis Model Assessment Index and Insulin-like Growth Factor-I and
Insulin-like Growth Factor Binding Protein-1 Levels to the Angiographic Outcome Measurements
DMLD DMSD D% Diameter Stenosis
Pearson
CC
Partial
CC
MSR
Increase
in R2
Pearson
CC
Partial
CC
MSR
Increase
in R2
Pearson
CC
Partial
CC
MSR
Increase
in R2
BMI 0.22 0.14 f 0.04 0.01 f 0.26* 0.24* f
GlucoseAUC 0.16 0.12 — 0.19 0.21 — 0.07 0.06 —
InsulinAUC 20.17 20.23 — 20.18 20.16 — 20.04 20.17 —
HOMA 20.03 20.01 NI 20.04 20.02 NI 0.01 0.02 NI
IGF-I 0.20 0.25* 0.05 0.23* 0.29* 0.07 0.18 0.19 —
IGFBP-1 20.01 0.02 NI 0.04 20.03 NI 20.13 20.00 NI
*p , 0.05. Baseline angiographic measurement, age, on-trial body mass index (BMI), serum lipoprotein (a) levels and low density lipoprotein (LDL) peak particle size were
controlled for when calculating partial correlation coefficients. In addition to on-trial BMI, baseline angiographic measurement and age were included as forced variables in the
multiple stepwise regression analysis. All other variables (on-trial glucoseAUC, insulinAUC, IGF-I, lipoprotein (a) and LDL size) were included in the final multiple regression
equation and their respective contribution to the value of R2 is shown.
CC 5 correlation coefficient; D 5 median change between the baseline and last follow-up angiogram for MLD and MSD and between the last follow-up and baseline
angiogram for percent diameter stenosis; f 5 forced variable; IGF-I 5 insulin-like growth factor-I; IGFBP-1 5 insulin-like growth factor binding protein-1; MLD 5 minimal
lumen diameter; MSD 5 mean segment diameter; MSR 5 multiple stepwise regression analysis; NI 5 not included in the model; other abbreviations as in Table 3.
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be potent activators of peroxisome proliferator-activated
receptor-alpha, which modulates the expression of many
different genes, such as those encoding different apolipopro-
teins and lipoprotein lipase (35). It is possible that activation
of peroxisome proliferator-activated receptor-alpha binding
to the promoter regions of either IGF-I or growth hormone
genes (as IGF-I synthesis is under strict growth hormone
regulation) may lead to a reduced synthesis of IGF-I.
Another fibrate compound, fenofibrate, has already been
reported to inhibit the growth of human vascular smooth
muscle cells in vitro and has been suggested as a possible
therapy for restenosis (36). Its antiproliferative effect does
not seem to be specific for a single growth factor, because
fenofibrate also seems to inhibit both platelet-derived
growth factor and basic fibroblast growth factor (36).
Insulin resistance and disease progression. No relations
were observed between the variables reflecting insulin resis-
tance and progression of CAD. Therefore, no support was
provided for the hypothesis that insulin resistance is causally
related to progression of CAD (37). It is noteworthy that
insulin sensitivity deteriorated dramatically in both study
groups during the five-year trial, albeit to a slightly lesser
extent in the bezafibrate-treated patients.
Implications and conclusions. The present study suggests
that serum IGF-I could be implicated in the progression of
premature CAD, independently of other coronary risk
factors. In contrast, the serum concentration of IGFBP-1
and other markers of insulin resistance were unrelated to
progression of CAD. The consistent reduction of serum
IGF-I levels by bezafibrate treatment could contribute to
the significantly slower progression of focal coronary ath-
erosclerosis of the bezafibrate-treated patients in BECAIT.
The mechanisms by which bezafibrate reduces circulating
IGF-I and by which IGF-I promotes coronary atheroscle-
rosis warrant further investigation.
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